Mydriaticum (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter muscle and ciliary body. By preventing parasympathetic stimulation, the iris muscles relax, leading to pupil enlargement, while the ciliary muscle loses its ability to accommodate, producing cycloplegia.

The appropriate dose of Mydriaticum is determined by the prescribing eye care professional based on the specific examination or procedure. The prescriber will select the number of drops, concentration, and timing that best suit the patient’s needs.

Safety data for tropicamide in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the health‑care provider. Women who are pregnant or breastfeeding should discuss potential risks with their clinician.

To place an order, submit an enquiry on the Mydriaticum product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Tropicamide provides rapid onset of dilation (within 15‑30 minutes) and a relatively short duration (4‑6 hours), making it suitable for routine examinations. Compared with longer‑acting agents such as phenylephrine or cyclopentolate, tropicamide offers quicker recovery of normal vision, which can be advantageous for outpatient settings.

Mydriaticum should be stored at room temperature, below 25 °C, in its original container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations to maintain potency and sterility.

Mydriaticum is applied topically to the eye as a sterile ophthalmic solution. The prescriber will instruct the patient on the number of drops per eye, the interval between doses, and any necessary precautions such as avoiding contact with other surfaces.

The most serious risks include acute angle‑closure glaucoma, severe allergic reactions affecting the eye, and systemic anticholinergic effects such as rapid heart rate or confusion, especially in susceptible individuals. Prompt medical attention is required if any of these symptoms develop.

Mydriaticum should be avoided in patients with known hypersensitivity to tropicamide or any component of the formulation, those with narrow‑angle or uncontrolled glaucoma, and individuals for whom pupil dilation could compromise ocular health without close supervision.